
Sign up to save your podcasts
Or


In this podcast recorded in BMA House in December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2024 issue of DTB. They discuss continuity of care in general practice and the benefits it offers (https://dtb.bmj.com/content/62/1/2). They discuss a safety alert issued by the Medicines and Healthcare products Regulatory Agency that highlights a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis associated with statins (https://dtb.bmj.com/content/62/1/4). The main article is an overview of the management of acne (https://dtb.bmj.com/content/62/1/6). They begin the podcast by providing a brief update on the results of a trial that assessed the effect of semaglutide on cardiovascular outcomes in people aged ≥45 years with cardiovascular disease (but not diabetes) and a BMI ≥27 kg/m2 (plot spoiler: make sure you know your ARRs from your RRRs).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening.
By BMJ Group4.8
44 ratings
In this podcast recorded in BMA House in December, James Cave (Editor-in-Chief) and David Phizackerley (Deputy Editor) talk about the January 2024 issue of DTB. They discuss continuity of care in general practice and the benefits it offers (https://dtb.bmj.com/content/62/1/2). They discuss a safety alert issued by the Medicines and Healthcare products Regulatory Agency that highlights a very small number of reports of new-onset or aggravation of pre-existing myasthenia gravis associated with statins (https://dtb.bmj.com/content/62/1/4). The main article is an overview of the management of acne (https://dtb.bmj.com/content/62/1/6). They begin the podcast by providing a brief update on the results of a trial that assessed the effect of semaglutide on cardiovascular outcomes in people aged ≥45 years with cardiovascular disease (but not diabetes) and a BMI ≥27 kg/m2 (plot spoiler: make sure you know your ARRs from your RRRs).
Please subscribe to the DTB podcast to get episodes automatically downloaded to your mobile device and computer. Also, please consider leaving us a review or a comment on the DTB Podcast iTunes podcast page (https://podcasts.apple.com/gb/podcast/dtb-podcast/id307773309). If you want to contact us please email [email protected]. Thank you for listening.

1,089 Listeners

893 Listeners

217 Listeners

2,115 Listeners

1,988 Listeners

35 Listeners

48 Listeners

90 Listeners

7 Listeners

5 Listeners

3 Listeners

1 Listeners

3 Listeners

10 Listeners

40 Listeners

14 Listeners

1 Listeners

51 Listeners

0 Listeners

6 Listeners

17 Listeners

16 Listeners

3 Listeners

21 Listeners

1,147 Listeners

23 Listeners

6 Listeners

18 Listeners

166 Listeners

2,906 Listeners

2,066 Listeners

838 Listeners

4 Listeners

0 Listeners